Omthera Pharma Inks $33.9M Series C

Omthera Pharmaceuticals Inc. has raised $33.9 million in Series B financing. Menlo Park, Calif.-based venture firm New Enterprise Associates led the round, with participation from existing shareholder Sofinnova Partners. Omthera will use the funds, in part, for Phase 3 clinical development of Omthera's novel Omega-3 fatty acid compound, Epanova, the company said in a release. Bedminster, New Jersey-based Omthera has raised a total of about $40.4 million in venture capital financing to date.

North AmericaUSBriefs